Literature DB >> 22178311

Evaluation of dual-source parallel RF excitation for diffusion-weighted whole-body MR imaging with background body signal suppression at 3.0 T.

Petra Mürtz1, Marius Kaschner, Frank Träber, Guido M Kukuk, Sarah M Büdenbender, Dirk Skowasch, Jürgen Gieseke, Hans H Schild, Winfried A Willinek.   

Abstract

PURPOSE: To evaluate the use of dual-source parallel RF excitation (TX) for diffusion-weighted whole-body MRI with background body signal suppression (DWIBS) at 3.0 T.
MATERIALS AND METHODS: Forty consecutive patients were examined on a clinical 3.0-T MRI system using a diffusion-weighted (DW) spin-echo echo-planar imaging sequence with a combination of short TI inversion recovery and slice-selective gradient reversal fat suppression. DWIBS of the neck (n=5), thorax (n=8), abdomen (n=6) and pelvis (n=21) was performed both with TX (2:56 min) and with standard single-source RF excitation (4:37 min). The quality of DW images and reconstructed inverted maximum intensity projections was visually judged by two readers (blinded to acquisition technique). Signal homogeneity and fat suppression were scored as "improved", "equal", "worse" or "ambiguous". Moreover, the apparent diffusion coefficient (ADC) values were measured in muscles, urinary bladder, lymph nodes and lesions.
RESULTS: By the use of TX, signal homogeneity was "improved" in 25/40 and "equal" in 15/40 cases. Fat suppression was "improved" in 17/40 and "equal" in 23/40 cases. These improvements were statistically significant (p<0.001, Wilcoxon signed-rank test). In five patients, fluid-related dielectric shading was present, which improved remarkably. The ADC values did not significantly differ for the two RF excitation methods (p=0.630 over all data, pairwise Student's t-test).
CONCLUSION: Dual-source parallel RF excitation improved image quality of DWIBS at 3.0 T with respect to signal homogeneity and fat suppression, reduced scan time by approximately one-third, and did not influence the measured ADC values.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22178311     DOI: 10.1016/j.ejrad.2011.11.024

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Diffusion-weighted MRI of the prostate: advantages of Zoomed EPI with parallel-transmit-accelerated 2D-selective excitation imaging.

Authors:  Kolja M Thierfelder; Michael K Scherr; Mike Notohamiprodjo; Jakob Weiß; Olaf Dietrich; Ullrich G Mueller-Lisse; Josef Pfeuffer; Konstantin Nikolaou; Daniel Theisen
Journal:  Eur Radiol       Date:  2014-08-27       Impact factor: 5.315

2.  Fat suppression techniques (STIR vs. SPAIR) on diffusion-weighted imaging of breast lesions at 3.0 T: preliminary experience.

Authors:  Sofia Brandão; Luísa Nogueira; Eduarda Matos; Rita Gouveia Nunes; Hugo Alexandre Ferreira; Joana Loureiro; Isabel Ramos
Journal:  Radiol Med       Date:  2015-02-10       Impact factor: 3.469

3.  Zoomed EPI DWI of Acute Spinal Ischemia Using a Parallel Transmission System.

Authors:  A Seeger; U Klose; F Bischof; J Strobel; U Ernemann; T-K Hauser
Journal:  Clin Neuroradiol       Date:  2014-08-29       Impact factor: 3.649

Review 4.  Parallel transmission for ultrahigh-field imaging.

Authors:  Francesco Padormo; Arian Beqiri; Joseph V Hajnal; Shaihan J Malik
Journal:  NMR Biomed       Date:  2015-05-19       Impact factor: 4.044

Review 5.  Screening of cancer predisposition syndromes.

Authors:  Haifa Al-Sarhani; Ravi V Gottumukkala; Angelo Don S Grasparil; Eric L Tung; Michael S Gee; Mary-Louise C Greer
Journal:  Pediatr Radiol       Date:  2021-04-01

6.  Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study.

Authors:  Katja De Paepe; Charlotte Bevernage; Frederik De Keyzer; Pascal Wolter; Olivier Gheysens; Ann Janssens; Raymond Oyen; Gregor Verhoef; Vincent Vandecaveye
Journal:  Cancer Imaging       Date:  2013-03-05       Impact factor: 3.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.